Stanford University School of Medicine Tuesday announced the availability of the Community Alliance to Test Coronavirus at Home (CATCH) study to estimate the true population prevalence of COVID-19 across the 8.5 million population of the greater San Francisco Bay Area, to help stop further undetected spread of COVID-19. in the effort to reopen schools, workplaces and communities.
The CATCH study is being led by Stanford Medicine researchers Yvonne Maldonado, MD, professor of paediatric infectious diseases and of health research and policy, Lorene Nelson, MD, associate professor of health research and policy and Dr Stephen Quake, professor of bioengineering and of applied physics and co-president of the Chan Zuckerberg Biohub.
Under the university's CATCH study, the home delivered self-collection kits will be rapidly deployed to carry out remote testing in a broad and representative sample of the population, including those underserved and vulnerable populations that might otherwise not be reached or tested. The study is enabled by the Vera Cloud Testing Platform including its novel Vera Home Test Kit, a gentle nasal swab self-collection kit that can be delivered directly to the homes of study participants by existing couriers and package delivery services.
Additionally, the CATCH Study is seeking participants in the San Francisco Bay Area to enroll for free. Every participant joins online, reports their symptoms and exposures to COVID-19 daily and may be offered a home test kit at no cost upon reporting. All tested participants are informed of their results online via personal password-protected account within the CATCH website, added the university.
All San Francisco Bay Area residents at least 18 years of age or older, including those with or without symptoms, residing in Alameda, Contra Costa, Marin, Monterey, Napa, San Benito, Santa Clara, Santa Cruz, San Francisco City & County, San Mateo, Solano and Sonoma can sign-up for the CATCH Study, concluded the university.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA